Bristol-Myers Squibb Announces Results of Phase 3 Trial of Yervoy
September 12, 2013 at 05:55 AM EDT
Bristol-Myers Squibb Company (NYSE: BMY ) today reported results from the Phase 3 randomized, double-blind clinical trial (Study 043) comparing Yervoy 10 mg/kg (ipilimumab) (n=399) to placebo (n=400)
